Oct. 4 at 8:20 PM
$RLYB
📍 Entries • Main Buy Zone:
$0.48 –
$0.54 • Breakout Buy: >
$0.56 with volume • Reload Zone:
$0.43 –
$0.48
🔍 Rationale RLYB is a cash-strong biotech with multiple near-term catalysts. The Nov 6th, 2025 earnings call (8am EST) is a key catalyst where management will update on lead drug RLYB116 and financials. Cohort 1 results (Q3 2025) will provide early safety and effect data, while Cohort 2 results (Q4 2025) could unlock Phase 2 trials — a critical step for biotech validation and investor interest. The company has ~
$45M cash, almost no debt, and over
$20M already secured from the REV102 sale to Recursion, giving them runway into 2027. Trading near
$0.50 (close to book value ~
$1.10), the stock is still undiscovered and underhyped, offering room for momentum if catalysts land.
⚠️ Risks / Warnings • Small biotech = very high volatility • Trial outcomes are binary — RLYB116 success or failure will dominate price • Thin liquidity — spikes may fade quickly
